Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
Early trial shows two-drug combo may help advanced lung cancer patients
This randomized phase 2 trial evaluated domvanalimab plus zimberelimab compared to zimberelimab alone or chemotherapy in patients with advan…
A Phase 2 trial suggests a two-drug combination might improve outcomes for some patients with advanced lung cancer compared to standard chem…
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
Phase I trial shows subcutaneous tislelizumab reaches high drug levels in lung cancer patients
This phase I trial evaluated subcutaneous versus intravenous tislelizumab in treatment-naive patients with advanced non-small cell lung canc…
Early data suggest subcutaneous tislelizumab injections may offer similar drug levels to intravenous forms for treating advanced lung cancer…
RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
New drug shows promise for KRASG12D lung and pancreatic cancers
This phase Ia trial evaluated RNK08954 in 36 patients with KRASG12D-mutant non-small cell lung cancer or pancreatic ductal adenocarcinoma.
An early trial of RNK08954 shrank tumors in 58% of lung cancer patients with a specific KRAS mutation.
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy
Lymph Nodes Hold Key to Beating Lung Cancer
This narrative review examines the tumor draining lymph nodes (TDLN) microenvironment remodeling in non-small cell lung cancer (NSCLC).
You wake up, sip your coffee, and take your morning walk.
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
Microwave Ablation Controls Breast Metastasis for Three Years
This case report and review of the literature describes ultrasound-guided microwave ablation in a 59-year-old female with metastatic breast …
A single session of microwave ablation kept a breast cancer metastasis under control for three years with no major side effects.
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
Doctors are still figuring out the best way to treat extensive-stage small cell lung cancer
This review examines the use of thoracic radiotherapy combined with chemoimmunotherapy in patients with extensive-stage small cell lung canc…
A review notes that while combining radiation with chemotherapy and immune therapy helps some patients, the best approach is still being stu…
Questions about Non-Small Cell Lung Cancer
Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Full answer →Does a phase III trial show sublobar resection is better than lobectomy for small peripheral non–small cell lung cancer?
Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Full answer →How do bispecific antibodies and CAR T-cell therapy work for advanced non–small cell lung cancer?
Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Full answer →What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Full answer →How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?
High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Full answer →Can you explain the global disparities in access to new therapies for advanced Non-Small Cell Lung Cancer?
Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Full answer →Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Full answer →Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Full answer →